Results published online today in the New England Journal of Medicine revealed that the world's most clinically advanced malaria vaccine candidate provides both infants and young children with significant protection against malaria. Two separate phase II trials reaffirmed earlier study results and support the ongoing efforts, pending regulatory approvals, to launch the phase III study of GlaxoSmithKline Biologicals' RTS,S/AS vaccine candidate across Africa.
2 new studies in the New England Journal of Medicine show malaria vaccine candidate advancing in Africa
- 8. 12 2008 (06:00)